上海市经济信息化委副主任葛东波表示，将通过人工智能与多组学技术的深度融合，加快化妆品研制范式升级，同时利用算力券、模型券、语料券等支持政 策，打造"AI+时尚制造"示范场景，释放创新资源，构建上海化妆品产业发展新优势。 在区域协同与产业布局上，政策也给予明确定位：奉贤区聚焦功效护肤、彩妆等赛道，打造"东方美谷·中国化妆品产业之都"；静安区着重发展皮肤科学、 AI与美妆融合，建设"美创静界"创新生态社区；青浦区发展功能性护肤品、香氛香水和国潮品牌；宝山区侧重植物化妆品与新锐品牌培育；上海化工区则布 局原料中试平台和生产基地，发展高端功能性原料。 化妆品产业作为时尚消费品产业的重要领域，是提升城市软实力的关键支撑。我国这一行业市场规模已连续两年迈过万亿元大关，成为全球第一大化妆品消 费市场。在此背景下，上海正积极抢占新一轮化妆品产业竞争的战略先机。今年上半年，上海化妆品零售额达685亿元，约占全国总量的三分之一。近期， 上海又发布《上海市促进化妆品产业高质量发展若干措施》，明确提出要培育一家市值达到500亿元的本土美妆企业。 在静安区打造的化妆品健康创新生态社区"美创静界"中，95后创业者肖思芮带领团队，刚刚推出 ...

Core Insights - The gene testing industry is facing significant challenges, including upstream monopolies squeezing profits, price wars downstream, and a decline in birth rates leading to reduced demand, which is putting pressure on overall profitability [4] - BGI Genomics has identified elderly health management as a key growth driver for the future, focusing on the elderly demographic as a core market [4][5] - With over 300 million people aged 60 and above in China, there is a surge in demand for chronic disease prevention, which may support BGI's market positioning during industry downturns [4][5] Industry Trends - The aging population in China is accelerating, with projections indicating that by 2024, 22% of the population will be aged 60 and above, equating to approximately 310 million individuals [5] - The silver economy is expected to reach a market size of 8.3 trillion yuan in 2024, potentially exceeding 20 trillion yuan by 2030 and 106 trillion yuan by 2050, covering various sectors including healthcare, elderly care services, and senior products [5] - Health care needs are particularly pronounced, with 75% of elderly individuals suffering from chronic diseases, creating substantial demand for prevention, diagnosis, and health management services [6] Company Strategy - BGI Genomics is focusing on precision health management driven by gene testing, targeting chronic diseases prevalent among the elderly, such as genetic metabolic disorders and cardiovascular diseases [7] - The company has launched several products for Alzheimer's disease risk assessment and cardiovascular disease risk evaluation, addressing the specific health needs of the aging population [8][9] - BGI's innovative approaches include the integration of artificial intelligence and multi-omics technologies to provide comprehensive health management solutions for the elderly [10] Technological Innovations - The introduction of the GeneT model allows for efficient interpretation of large genomic datasets, enhancing the accuracy of disease risk predictions for the elderly [10] - The "i99 Smart Health" multi-omics health management system offers personalized health management plans by integrating various data types, addressing common health issues faced by the elderly [10] - These technological advancements aim to lower testing costs and make gene testing more accessible, transforming it from a luxury service to a more widely available option for the elderly [10][11]